Development of PARP and Immune-Checkpoint Inhibitor Combinations

Cancer Research - United States
doi 10.1158/0008-5472.can-18-2652
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Immune Checkpoint Inhibitor Combinations in Solid Tumors: Opportunities and Challenges

Immunotherapy
OncologyAllergyImmunology
2016English

Immune Checkpoint Inhibitor-Induced Fanconi Syndrome

Cureus
2020English

Immune Checkpoint Inhibitor Nephrotoxicity: Update 2020

Kidney360
2020English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

Reporting of Immune Checkpoint Inhibitor-Associated Myocarditis – Authors' Reply

The Lancet
Medicine
2018English

Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy

Case Reports in Oncological Medicine
Oncology
2017English

Can an Immune Checkpoint Inhibitor (Sometimes) Make Things Worse?

Clinical Cancer Research
Cancer ResearchOncology
2017English

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Archives of Pathology and Laboratory Medicine
MedicineForensic MedicinePathologyMedical Laboratory Technology
2020English

PO-484 Development of a Two-Step Screening-And-Confirmation Approach to Efficiently Identify Synergistic Drug Combinations With the Parp Inhibitor Niraparib

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy